Literature DB >> 28218037

Immunotoxin: A new tool for cancer therapy.

Hossein Allahyari1, Sahar Heidari1, Mehdi Ghamgosha1, Parvaneh Saffarian2, Jafar Amani3.   

Abstract

Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation. "Immunotoxin Therapy" is a promising way of cancer therapy that is mentioned in this field. Immunotoxins are made from a toxin attaching to an antibody target proteins present on cancer cells. The first-generation immunotoxins were made of a full-length toxin attached to whole monoclonal antibodies. But, these immunotoxins could bind to normal cells. DAB389IL2 was the first immunotoxin approved by the Food and Drug Administration. Current trends and researches are ongoing on finding proteins that in combination with immunotoxins have minimal immunogenicity and the most potency for target cell killing.

Entities:  

Keywords:  Toxins; antibody; cancer therapy; immunotoxins

Mesh:

Substances:

Year:  2017        PMID: 28218037     DOI: 10.1177/1010428317692226

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

Review 3.  Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Stefan Dübel; Reinhard E Voll
Journal:  Cells       Date:  2020-07-06       Impact factor: 6.600

4.  Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.

Authors:  Lawrence H Cheung; Yunli Zhao; Ana Alvarez-Cienfuegos; Khalid A Mohamedali; Yu J Cao; Walter N Hittelman; Michael G Rosenblum
Journal:  J Exp Clin Cancer Res       Date:  2019-07-30

5.  Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A.

Authors:  Byeong Sung Lee; Yumi Lee; Jisoo Park; Bo Seok Jeong; Migyeong Jo; Sang Taek Jung; Tae Hyeon Yoo
Journal:  J Biol Eng       Date:  2019-06-21       Impact factor: 4.355

Review 6.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

7.  Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.

Authors:  Sangsu Park; Minh Quan Nguyen; Huynh Kim Khanh Ta; Minh Tan Nguyen; Gunsup Lee; Chong Jai Kim; Yeon Jin Jang; Han Choe
Journal:  Int J Mol Sci       Date:  2021-06-17       Impact factor: 6.208

8.  Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug

Authors:  Peyman Bemani; Mozafar Mohammadi; Ali Hakakian
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27

9.  The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.

Authors:  Shengjian Huang; Changying Jiang; Hui Zhang; Taylor Bell; Hui Guo; Yang Liu; Yixin Yao; Dongfeng Zeng; Makhdum Ahmed; Krystle Nomie; Leo Zhang; Michael Wang
Journal:  Blood Cancer J       Date:  2018-03-20       Impact factor: 11.037

10.  Molecular cloning and in-depth bioinformatics analysis of type II ribosome-inactivating protein isolated from Sambucus ebulus.

Authors:  Masoumeh Rezaei-Moshaei; Ali Bandehagh; Ali Dehestani; Ali Pakdin-Parizi; Majid Golkar
Journal:  Saudi J Biol Sci       Date:  2020-02-17       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.